Mark Silberrad
About Mark Silberrad
Mark Silberrad is a Haematology Key Account Manager at Bristol-Myers Squibb with over 35 years of experience in the pharmaceutical and medical fields.
Title
Mark Silberrad is currently serving as a Haematology Key Account Manager at Bristol-Myers Squibb. His role focuses on managing key accounts within the haematology sector, leveraging over 17 years of specific experience in this field.
Current Company
Mark Silberrad is employed at Bristol-Myers Squibb, where he holds the position of Haematology Key Account Manager. Bristol-Myers Squibb is a renowned global biopharmaceutical company, and Mark's role is critical in fostering relationships and ensuring the effective management of key accounts in the haematology division.
Previous Work Experience
Mark Silberrad has an extensive career history that includes roles at several major pharmaceutical companies. He worked at Sanofi as an Oncology and Haematology Specialist from 2005 to 2006. Prior to that, he served as a Senior Oncology Specialist at Roche from 2000 to 2003. From 1998 to 2000, he was an Oncology and Haematology Specialist at Novartis. His earlier career includes a position as a Hospital Representative at AstraZeneca from 1994 to 1998 and as a Medical Representative at Norgine from 1988 to 1994.
Industry Experience
With a career spanning over 35 years in the pharmaceutical and medical fields, Mark Silberrad has amassed significant experience across various roles and companies. His expertise encompasses both oncology and haematology specialties. This extensive background has enabled him to develop deep insights and a strategic approach to account management within these sectors.
Career Beginnings
Mark Silberrad started his career in the pharmaceutical industry in 1988 at Norgine, where he worked as a Medical Representative for six years. This foundational experience provided him with a solid grounding in the industry, setting the stage for his subsequent roles in oncology and haematology across other leading pharmaceutical companies.